ID   CDK5_HUMAN              Reviewed;         292 AA.
AC   Q00535; A1XKG3;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-1998, sequence version 3.
DT   12-OCT-2022, entry version 232.
DE   RecName: Full=Cyclin-dependent kinase 5 {ECO:0000312|HGNC:HGNC:1774};
DE            EC=2.7.11.1;
DE   AltName: Full=Cell division protein kinase 5 {ECO:0000305};
DE   AltName: Full=Cyclin-dependent-like kinase 5;
DE   AltName: Full=Serine/threonine-protein kinase PSSALRE {ECO:0000250|UniProtKB:Q03114};
DE   AltName: Full=Tau protein kinase II catalytic subunit {ECO:0000250|UniProtKB:Q02399};
DE            Short=TPKII catalytic subunit {ECO:0000250|UniProtKB:Q02399};
GN   Name=CDK5 {ECO:0000312|HGNC:HGNC:1774};
GN   Synonyms=CDKN5 {ECO:0000312|HGNC:HGNC:1774}, PSSALRE
GN   {ECO:0000250|UniProtKB:P49615};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=1639063; DOI=10.1002/j.1460-2075.1992.tb05360.x;
RA   Meyerson M., Enders G.H., Wu C.-L., Su L.-K., Gorka C., Nelson C.,
RA   Harlow E., Tsai L.-H.;
RT   "A family of human cdc2-related protein kinases.";
RL   EMBO J. 11:2909-2917(1992).
RN   [2]
RP   SEQUENCE REVISION.
RA   Meyerson M.;
RL   Submitted (FEB-1993) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, INTERACTION WITH CTNNB1, AND FUNCTION IN WNT/B-CATENIN
RP   SIGNALING PATHWAY.
RC   TISSUE=Testis;
RX   PubMed=19693690; DOI=10.1007/s11033-009-9752-7;
RA   Li Q., Liu X., Zhang M., Ye G., Qiao Q., Ling Y., Wu Y., Zhang Y., Yu L.;
RT   "Characterization of a novel human CDK5 splicing variant that inhibits
RT   Wnt/beta-catenin signaling.";
RL   Mol. Biol. Rep. 37:2415-2421(2010).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Hu X., Xu Y., Zhang B., Peng X., Yuan J., Qiang B.;
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   ACTIVITY REGULATION BY ROSCOVITINE AND OLOMOUCINE.
RX   PubMed=9030781; DOI=10.1111/j.1432-1033.1997.t01-2-00527.x;
RA   Meijer L., Borgne A., Mulner O., Chong J.P.J., Blow J.J., Inagaki N.,
RA   Inagaki M., Delcros J.-G., Moulinoux J.-P.;
RT   "Biochemical and cellular effects of roscovitine, a potent and selective
RT   inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.";
RL   Eur. J. Biochem. 243:527-536(1997).
RN   [9]
RP   FUNCTION IN AXON GROWTH.
RX   PubMed=9822744; DOI=10.1523/jneurosci.18-23-09858.1998;
RA   Paglini G., Pigino G., Kunda P., Morfini G., Maccioni R., Quiroga S.,
RA   Ferreira A., Caceres A.;
RT   "Evidence for the participation of the neuron-specific CDK5 activator P35
RT   during laminin-enhanced axonal growth.";
RL   J. Neurosci. 18:9858-9869(1998).
RN   [10]
RP   PHOSPHORYLATION AT SER-159.
RX   PubMed=10500146; DOI=10.1073/pnas.96.20.11156;
RA   Sharma P., Sharma M., Amin N.D., Albers R.W., Pant H.C.;
RT   "Regulation of cyclin-dependent kinase 5 catalytic activity by
RT   phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:11156-11160(1999).
RN   [11]
RP   FUNCTION AS P35/CDK5R1 KINASE.
RX   PubMed=12393264; DOI=10.1016/s0169-328x(02)00409-6;
RA   Kerokoski P., Suuronen T., Salminen A., Soininen H., Pirttilae T.;
RT   "Influence of phosphorylation of p35, an activator of cyclin-dependent
RT   kinase 5 (cdk5), on the proteolysis of p35.";
RL   Brain Res. Mol. Brain Res. 106:50-56(2002).
RN   [12]
RP   INTERACTION WITH AATK.
RX   PubMed=14521924; DOI=10.1016/j.bbrc.2003.08.143;
RA   Honma N., Asada A., Takeshita S., Enomoto M., Yamakawa E., Tsutsumi K.,
RA   Saito T., Satoh T., Itoh H., Kaziro Y., Kishimoto T., Hisanaga S.;
RT   "Apoptosis-associated tyrosine kinase is a Cdk5 activator p35 binding
RT   protein.";
RL   Biochem. Biophys. Res. Commun. 310:398-404(2003).
RN   [13]
RP   FUNCTION AS MEF2A KINASE, ACTIVITY REGULATION, AND SUBCELLULAR LOCATION.
RX   PubMed=12691662; DOI=10.1016/s0896-6273(03)00191-0;
RA   Gong X., Tang X., Wiedmann M., Wang X., Peng J., Zheng D., Blair L.A.C.,
RA   Marshall J., Mao Z.;
RT   "Cdk5-mediated inhibition of the protective effects of transcription factor
RT   MEF2 in neurotoxicity-induced apoptosis.";
RL   Neuron 38:33-46(2003).
RN   [14]
RP   FUNCTION AS P35 KINASE, SUBCELLULAR LOCATION, AND ACTIVITY REGULATION.
RX   PubMed=15992363; DOI=10.1111/j.1471-4159.2005.03301.x;
RA   Zhu Y.-S., Saito T., Asada A., Maekawa S., Hisanaga S.;
RT   "Activation of latent cyclin-dependent kinase 5 (Cdk5)-p35 complexes by
RT   membrane dissociation.";
RL   J. Neurochem. 94:1535-1545(2005).
RN   [15]
RP   FUNCTION AS P35/CDK5R KINASE.
RX   PubMed=17121855; DOI=10.1074/jbc.m610541200;
RA   Kamei H., Saito T., Ozawa M., Fujita Y., Asada A., Bibb J.A., Saido T.C.,
RA   Sorimachi H., Hisanaga S.;
RT   "Suppression of calpain-dependent cleavage of the CDK5 activator p35 to p25
RT   by site-specific phosphorylation.";
RL   J. Biol. Chem. 282:1687-1694(2007).
RN   [16]
RP   FUNCTION AS CTNNB1 AND CTNND2 KINASE, INTERACTION WITH CTNNB1 AND CTNND2,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17009320; DOI=10.1002/jcb.21041;
RA   Munoz J.P., Huichalaf C.H., Orellana D., Maccioni R.B.;
RT   "cdk5 modulates beta- and delta-catenin/Pin1 interactions in neuronal
RT   cells.";
RL   J. Cell. Biochem. 100:738-749(2007).
RN   [17]
RP   FUNCTION AS P53/TP53 KINASE, INTERACTION WITH P53/TP53, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=17591690; DOI=10.1242/jcs.03468;
RA   Lee J.-H., Kim H.-S., Lee S.-J., Kim K.-T.;
RT   "Stabilization and activation of p53 induced by Cdk5 contributes to
RT   neuronal cell death.";
RL   J. Cell Sci. 120:2259-2271(2007).
RN   [18]
RP   FUNCTION AS PXN KINASE.
RX   PubMed=18042622; DOI=10.1242/jcs.018218;
RA   Miyamoto Y., Yamauchi J., Chan J.R., Okada A., Tomooka Y., Hisanaga S.,
RA   Tanoue A.;
RT   "Cdk5 regulates differentiation of oligodendrocyte precursor cells through
RT   the direct phosphorylation of paxillin.";
RL   J. Cell Sci. 120:4355-4366(2007).
RN   [19]
RP   FUNCTION AS HUNTINGTIN KINASE, AND ACTIVITY REGULATION BY ROSCOVITINE.
RX   PubMed=17611284; DOI=10.1523/jneurosci.1831-07.2007;
RA   Anne S.L., Saudou F., Humbert S.;
RT   "Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by
RT   DNA damage and regulates wild-type and mutant huntingtin toxicity in
RT   neurons.";
RL   J. Neurosci. 27:7318-7328(2007).
RN   [20]
RP   FUNCTION AS P35/CDK5R KINASE, INTERACTION WITH P35/CDK5R, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=17671990; DOI=10.1002/jnr.21438;
RA   Sato K., Zhu Y.-S., Saito T., Yotsumoto K., Asada A., Hasegawa M.,
RA   Hisanaga S.;
RT   "Regulation of membrane association and kinase activity of Cdk5-p35 by
RT   phosphorylation of p35.";
RL   J. Neurosci. Res. 85:3071-3078(2007).
RN   [21]
RP   PHOSPHORYLATION AT TYR-15 BY EPHA4.
RX   PubMed=17143272; DOI=10.1038/nn1811;
RA   Fu W.Y., Chen Y., Sahin M., Zhao X.S., Shi L., Bikoff J.B., Lai K.O.,
RA   Yung W.H., Fu A.K., Greenberg M.E., Ip N.Y.;
RT   "Cdk5 regulates EphA4-mediated dendritic spine retraction through an
RT   ephexin1-dependent mechanism.";
RL   Nat. Neurosci. 10:67-76(2007).
RN   [22]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18507738; DOI=10.1111/j.1471-4159.2008.05500.x;
RA   Asada A., Yamamoto N., Gohda M., Saito T., Hayashi N., Hisanaga S.;
RT   "Myristoylation of p39 and p35 is a determinant of cytoplasmic or nuclear
RT   localization of active cyclin-dependent kinase 5 complexes.";
RL   J. Neurochem. 106:1325-1336(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-72, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [24]
RP   FUNCTION AS HDAC REGULATOR.
RX   PubMed=19081376; DOI=10.1016/j.neuron.2008.10.015;
RA   Kim D., Frank C.L., Dobbin M.M., Tsunemoto R.K., Tu W., Peng P.L.,
RA   Guan J.S., Lee B.H., Moy L.Y., Giusti P., Broodie N., Mazitschek R.,
RA   Delalle I., Haggarty S.J., Neve R.L., Lu Y., Tsai L.H.;
RT   "Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity.";
RL   Neuron 60:803-817(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-72, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [27]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-56, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [28]
RP   FUNCTION IN ANGIOGENESIS.
RX   PubMed=20826806; DOI=10.1074/jbc.m110.126177;
RA   Liebl J., Weitensteiner S.B., Vereb G., Takacs L., Fuerst R., Vollmar A.M.,
RA   Zahler S.;
RT   "Cyclin-dependent kinase 5 regulates endothelial cell migration and
RT   angiogenesis.";
RL   J. Biol. Chem. 285:35932-35943(2010).
RN   [29]
RP   FUNCTION AS NOS3 KINASE.
RX   PubMed=20213743; DOI=10.1002/jcb.22515;
RA   Lee C.-H., Wei Y.-W., Huang Y.-T., Lin Y.-T., Lee Y.-C., Lee K.-H.,
RA   Lu P.-J.;
RT   "CDK5 phosphorylates eNOS at Ser-113 and regulates NO production.";
RL   J. Cell. Biochem. 110:112-117(2010).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [31]
RP   INHIBITORS.
RX   PubMed=21144757; DOI=10.1016/j.bmc.2010.11.022;
RA   Jain P., Flaherty P.T., Yi S., Chopra I., Bleasdell G., Lipay J.,
RA   Ferandin Y., Meijer L., Madura J.D.;
RT   "Design, synthesis, and testing of an 6-O-linked series of benzimidazole
RT   based inhibitors of CDK5/p25.";
RL   Bioorg. Med. Chem. 19:359-373(2011).
RN   [32]
RP   FUNCTION AS SRC KINASE.
RX   PubMed=21442427; DOI=10.1007/s00018-011-0638-1;
RA   Pan Q., Qiao F., Gao C., Norman B., Optican L., Zelenka P.S.;
RT   "Cdk5 targets active Src for ubiquitin-dependent degradation by
RT   phosphorylating Src(S75).";
RL   Cell. Mol. Life Sci. 68:3425-3436(2011).
RN   [33]
RP   FUNCTION AS VIM KINASE, AND SUBCELLULAR LOCATION.
RX   PubMed=21465480; DOI=10.1002/jcp.22782;
RA   Lee K.Y., Liu L., Jin Y., Fu S.B., Rosales J.L.;
RT   "Cdk5 mediates vimentin Ser56 phosphorylation during GTP-induced secretion
RT   by neutrophils.";
RL   J. Cell. Physiol. 227:739-750(2012).
RN   [34]
RP   ACTIVITY REGULATION, AND INTERACTION WITH GSTP1.
RX   PubMed=21668448; DOI=10.1111/j.1471-4159.2011.07343.x;
RA   Sun K.H., Chang K.H., Clawson S., Ghosh S., Mirzaei H., Regnier F.,
RA   Shah K.;
RT   "Glutathione-S-transferase P1 is a critical regulator of Cdk5 kinase
RT   activity.";
RL   J. Neurochem. 118:902-914(2011).
RN   [35]
RP   FUNCTION AS TONEBP/NFAT5 KINASE.
RX   PubMed=21209322; DOI=10.1091/mbc.e10-08-0681;
RA   Gallazzini M., Heussler G.E., Kunin M., Izumi Y., Burg M.B., Ferraris J.D.;
RT   "High NaCl-induced activation of CDK5 increases phosphorylation of the
RT   osmoprotective transcription factor TonEBP/OREBP at threonine 135, which
RT   contributes to its rapid nuclear localization.";
RL   Mol. Biol. Cell 22:703-714(2011).
RN   [36]
RP   FUNCTION AS SH3GLB1 KINASE.
RX   PubMed=21499257; DOI=10.1038/ncb2217;
RA   Wong A.S., Lee R.H., Cheung A.Y., Yeung P.K., Chung S.K., Cheung Z.H.,
RA   Ip N.Y.;
RT   "Cdk5-mediated phosphorylation of endophilin B1 is required for induced
RT   autophagy in models of Parkinson's disease.";
RL   Nat. Cell Biol. 13:568-579(2011).
RN   [37]
RP   FUNCTION AS EPRS KINASE.
RX   PubMed=21220307; DOI=10.1073/pnas.1011275108;
RA   Arif A., Jia J., Moodt R.A., DiCorleto P.E., Fox P.L.;
RT   "Phosphorylation of glutamyl-prolyl tRNA synthetase by cyclin-dependent
RT   kinase 5 dictates transcript-selective translational control.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:1415-1420(2011).
RN   [38]
RP   REVIEW.
RX   PubMed=11584302; DOI=10.1038/35096019;
RA   Dhavan R., Tsai L.H.;
RT   "A decade of CDK5.";
RL   Nat. Rev. Mol. Cell Biol. 2:749-759(2001).
RN   [39]
RP   REVIEW ON INHIBITORS, AND GENE FAMILY.
RX   PubMed=19238148; DOI=10.1038/nrc2602;
RA   Malumbres M., Barbacid M.;
RT   "Cell cycle, CDKs and cancer: a changing paradigm.";
RL   Nat. Rev. Cancer 9:153-166(2009).
RN   [40]
RP   REVIEW ON NEURONAL PHYSIOLOGY.
RX   PubMed=19782409; DOI=10.1016/j.tins.2009.07.002;
RA   Jessberger S., Gage F.H., Eisch A.J., Lagace D.C.;
RT   "Making a neuron: Cdk5 in embryonic and adult neurogenesis.";
RL   Trends Neurosci. 32:575-582(2009).
RN   [41]
RP   FUNCTION.
RX   PubMed=20061803; DOI=10.4161/cc.9.2.10466;
RA   Lalioti V., Pulido D., Sandoval I.V.;
RT   "Cdk5, the multifunctional surveyor.";
RL   Cell Cycle 9:284-311(2010).
RN   [42]
RP   REVIEW ON REGULATION.
RX   PubMed=21044075; DOI=10.1111/j.1471-4159.2010.07050.x;
RA   Hisanaga S., Endo R.;
RT   "Regulation and role of cyclin-dependent kinase activity in neuronal
RT   survival and death.";
RL   J. Neurochem. 115:1309-1321(2010).
RN   [43]
RP   REVIEW ON NEURON DEVELOPMENT.
RX   PubMed=21415596; DOI=10.4161/cc.10.8.15328;
RA   Zhang J., Herrup K.;
RT   "Nucleocytoplasmic Cdk5 is involved in neuronal cell cycle and death in
RT   post-mitotic neurons.";
RL   Cell Cycle 10:1208-1214(2011).
RN   [44]
RP   REVIEW ON NEURON DEVELOPMENT.
RX   PubMed=21600237; DOI=10.1016/j.mad.2011.04.011;
RA   Zhu J., Li W., Mao Z.;
RT   "Cdk5: Mediator of neuronal development, death and the response to DNA
RT   damage.";
RL   Mech. Ageing Dev. 132:389-394(2011).
RN   [45]
RP   REVIEW ON NEURONS.
RX   PubMed=21473899; DOI=10.1016/j.pneurobio.2011.03.006;
RA   Lopes J.P., Agostinho P.;
RT   "Cdk5: multitasking between physiological and pathological conditions.";
RL   Prog. Neurobiol. 94:49-63(2011).
RN   [46]
RP   FUNCTION, AND INTERACTION WITH CLOCK.
RX   PubMed=24235147; DOI=10.1074/jbc.m113.494856;
RA   Kwak Y., Jeong J., Lee S., Park Y.U., Lee S.A., Han D.H., Kim J.H.,
RA   Ohshima T., Mikoshiba K., Suh Y.H., Cho S., Park S.K.;
RT   "Cyclin-dependent kinase 5 (Cdk5) regulates the function of CLOCK protein
RT   by direct phosphorylation.";
RL   J. Biol. Chem. 288:36878-36889(2013).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-17, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [48]
RP   INVOLVEMENT IN LIS7.
RX   PubMed=25560765; DOI=10.1007/s00439-014-1522-5;
RA   Magen D., Ofir A., Berger L., Goldsher D., Eran A., Katib N., Nijem Y.,
RA   Vlodavsky E., Tzur S., Zur S., Behar D.M., Fellig Y., Mandel H.;
RT   "Autosomal recessive lissencephaly with cerebellar hypoplasia is associated
RT   with a loss-of-function mutation in CDK5.";
RL   Hum. Genet. 134:305-314(2015).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) IN COMPLEX WITH P25, AND MUTAGENESIS
RP   OF SER-159.
RX   PubMed=11583627; DOI=10.1016/s1097-2765(01)00343-4;
RA   Tarricone C., Dhavan R., Peng J., Areces L.B., Tsai L.-H., Musacchio A.;
RT   "Structure and regulation of the CDK5-p25(nck5a) complex.";
RL   Mol. Cell 8:657-669(2001).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS).
RX   PubMed=16039528; DOI=10.1016/j.chembiol.2005.05.011;
RA   Ahn J.S., Radhakrishnan M.L., Mapelli M., Choi S., Tidor B., Cuny G.D.,
RA   Musacchio A., Yeh L.A., Kosik K.S.;
RT   "Defining Cdk5 ligand chemical space with small molecule inhibitors of tau
RT   phosphorylation.";
RL   Chem. Biol. 12:811-823(2005).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) IN COMPLEX WITH INHIBITORS AND P25,
RP   AND PHOSPHORYLATION AT TYR-15.
RX   PubMed=15689152; DOI=10.1021/jm049323m;
RA   Mapelli M., Massimiliano L., Crovace C., Seeliger M.A., Tsai L.H.,
RA   Meijer L., Musacchio A.;
RT   "Mechanism of CDK5/p25 binding by CDK inhibitors.";
RL   J. Med. Chem. 48:671-679(2005).
RN   [52]
RP   VARIANT [LARGE SCALE ANALYSIS] ASP-225.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Proline-directed serine/threonine-protein kinase essential
CC       for neuronal cell cycle arrest and differentiation and may be involved
CC       in apoptotic cell death in neuronal diseases by triggering abortive
CC       cell cycle re-entry. Interacts with D1 and D3-type G1 cyclins.
CC       Phosphorylates SRC, NOS3, VIM/vimentin, p35/CDK5R1, MEF2A, SIPA1L1,
CC       SH3GLB1, PXN, PAK1, MCAM/MUC18, SEPT5, SYN1, DNM1, AMPH, SYNJ1, CDK16,
CC       RAC1, RHOA, CDC42, TONEBP/NFAT5, MAPT/TAU, MAP1B, histone H1, p53/TP53,
CC       HDAC1, APEX1, PTK2/FAK1, huntingtin/HTT, ATM, MAP2, NEFH and NEFM.
CC       Regulates several neuronal development and physiological processes
CC       including neuronal survival, migration and differentiation, axonal and
CC       neurite growth, synaptogenesis, oligodendrocyte differentiation,
CC       synaptic plasticity and neurotransmission, by phosphorylating key
CC       proteins. Negatively regulates the CACNA1B/CAV2.2 -mediated Ca(2+)
CC       release probability at hippocampal neuronal soma and synaptic terminals
CC       (By similarity). Activated by interaction with CDK5R1 (p35) and CDK5R2
CC       (p39), especially in postmitotic neurons, and promotes CDK5R1 (p35)
CC       expression in an autostimulation loop. Phosphorylates many downstream
CC       substrates such as Rho and Ras family small GTPases (e.g. PAK1, RAC1,
CC       RHOA, CDC42) or microtubule-binding proteins (e.g. MAPT/TAU, MAP2,
CC       MAP1B), and modulates actin dynamics to regulate neurite growth and/or
CC       spine morphogenesis. Phosphorylates also exocytosis associated proteins
CC       such as MCAM/MUC18, SEPT5, SYN1, and CDK16/PCTAIRE1 as well as
CC       endocytosis associated proteins such as DNM1, AMPH and SYNJ1 at
CC       synaptic terminals. In the mature central nervous system (CNS),
CC       regulates neurotransmitter movements by phosphorylating substrates
CC       associated with neurotransmitter release and synapse plasticity;
CC       synaptic vesicle exocytosis, vesicles fusion with the presynaptic
CC       membrane, and endocytosis. Promotes cell survival by activating anti-
CC       apoptotic proteins BCL2 and STAT3, and negatively regulating of
CC       JNK3/MAPK10 activity. Phosphorylation of p53/TP53 in response to
CC       genotoxic and oxidative stresses enhances its stabilization by
CC       preventing ubiquitin ligase-mediated proteasomal degradation, and
CC       induces transactivation of p53/TP53 target genes, thus regulating
CC       apoptosis. Phosphorylation of p35/CDK5R1 enhances its stabilization by
CC       preventing calpain-mediated proteolysis producing p25/CDK5R1 and
CC       avoiding ubiquitin ligase-mediated proteasomal degradation. During
CC       aberrant cell-cycle activity and DNA damage, p25/CDK5 activity elicits
CC       cell-cycle activity and double-strand DNA breaks that precedes neuronal
CC       death by deregulating HDAC1. DNA damage triggered phosphorylation of
CC       huntingtin/HTT in nuclei of neurons protects neurons against
CC       polyglutamine expansion as well as DNA damage mediated toxicity.
CC       Phosphorylation of PXN reduces its interaction with PTK2/FAK1 in
CC       matrix-cell focal adhesions (MCFA) during oligodendrocytes (OLs)
CC       differentiation. Negative regulator of Wnt/beta-catenin signaling
CC       pathway. Activator of the GAIT (IFN-gamma-activated inhibitor of
CC       translation) pathway, which suppresses expression of a post-
CC       transcriptional regulon of proinflammatory genes in myeloid cells;
CC       phosphorylates the linker domain of glutamyl-prolyl tRNA synthetase
CC       (EPRS) in a IFN-gamma-dependent manner, the initial event in assembly
CC       of the GAIT complex. Phosphorylation of SH3GLB1 is required for
CC       autophagy induction in starved neurons. Phosphorylation of TONEBP/NFAT5
CC       in response to osmotic stress mediates its rapid nuclear localization.
CC       MEF2 is inactivated by phosphorylation in nucleus in response to
CC       neurotoxin, thus leading to neuronal apoptosis. APEX1 AP-
CC       endodeoxyribonuclease is repressed by phosphorylation, resulting in
CC       accumulation of DNA damage and contributing to neuronal death. NOS3
CC       phosphorylation down regulates NOS3-derived nitrite (NO) levels. SRC
CC       phosphorylation mediates its ubiquitin-dependent degradation and thus
CC       leads to cytoskeletal reorganization. May regulate endothelial cell
CC       migration and angiogenesis via the modulation of lamellipodia
CC       formation. Involved in dendritic spine morphogenesis by mediating the
CC       EFNA1-EPHA4 signaling. The complex p35/CDK5 participates in the
CC       regulation of the circadian clock by modulating the function of CLOCK
CC       protein: phosphorylates CLOCK at 'Thr-451' and 'Thr-461' and regulates
CC       the transcriptional activity of the CLOCK-ARNTL/BMAL1 heterodimer in
CC       association with altered stability and subcellular distribution.
CC       {ECO:0000250|UniProtKB:Q03114, ECO:0000269|PubMed:12393264,
CC       ECO:0000269|PubMed:12691662, ECO:0000269|PubMed:15992363,
CC       ECO:0000269|PubMed:17009320, ECO:0000269|PubMed:17121855,
CC       ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17611284,
CC       ECO:0000269|PubMed:17671990, ECO:0000269|PubMed:18042622,
CC       ECO:0000269|PubMed:19081376, ECO:0000269|PubMed:19693690,
CC       ECO:0000269|PubMed:20061803, ECO:0000269|PubMed:20213743,
CC       ECO:0000269|PubMed:20826806, ECO:0000269|PubMed:21209322,
CC       ECO:0000269|PubMed:21220307, ECO:0000269|PubMed:21442427,
CC       ECO:0000269|PubMed:21465480, ECO:0000269|PubMed:21499257,
CC       ECO:0000269|PubMed:24235147, ECO:0000269|PubMed:9822744}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- ACTIVITY REGULATION: Inhibited by 2-(1-ethyl-2-hydroxyethylamino)-6-
CC       benzylamino-9-isopropylpurine (roscovitine), 1-isopropyl-4-aminobenzyl-
CC       6-ether-linked benzimidazoles, resveratrol, AT-7519 and olomoucine.
CC       Activated by CDK5R1 (p35) and CDK5R2 (p39) during the development of
CC       the nervous system; degradation of CDK5R1 (p35) and CDK5R2 (p39) by
CC       proteasome result in down regulation of kinase activity, during this
CC       process, CDK5 phosphorylates p35 and induces its ubiquitination and
CC       subsequent degradation. Kinase activity is mainly determined by the
CC       amount of p35 available and subcellular location; reversible
CC       association to plasma membrane inhibits activity. Long-term
CC       inactivation as well as CDK5R1 (p25)-mediated hyperactivation of CDK5
CC       triggers cell death. The pro-death activity of hyperactivated CDK5 is
CC       suppressed by membrane association of CDK5, via myristoylation of p35.
CC       Brain-derived neurotrophic factor, glial-derived neurotrophic factor,
CC       nerve growth factor (NGF), retinoic acid, laminin and neuregulin
CC       promote activity. Neurotoxicity enhances nuclear activity, thus leading
CC       to MEF2 phosphorylation and inhibition prior to apoptosis of cortical
CC       neurons. Repression by GSTP1 via p25/p35 translocation prevents
CC       neurodegeneration. {ECO:0000269|PubMed:12691662,
CC       ECO:0000269|PubMed:15992363, ECO:0000269|PubMed:17611284,
CC       ECO:0000269|PubMed:21668448, ECO:0000269|PubMed:9030781}.
CC   -!- SUBUNIT: Heterodimer composed of a catalytic subunit CDK5 and a
CC       regulatory subunit CDK5R1 (p25) and macromolecular complex composed of
CC       at least CDK5, CDK5R1 (p35) and CDK5RAP1 or CDK5RAP2 or CDK5RAP3. Only
CC       the heterodimer shows kinase activity. Under neurotoxic stress and
CC       neuronal injury conditions, p35 is cleaved by calpain to generate p25
CC       that hyperactivates CDK5, that becomes functionally disabled and often
CC       toxic. Found in a trimolecular complex with CABLES1 and ABL1. Interacts
CC       with CABLES1 and CABLES2 (By similarity). Interacts with AATK and
CC       GSTP1. Binds to HDAC1 when in complex with p25. Interaction with
CC       myristoylation p35 promotes CDK5 association with membranes. Both
CC       isoforms 1 and 2 interacts with beta-catenin/CTNNB1. Interacts with
CC       delta-catenin/CTNND2 and APEX1. Interacts with P53/TP53 in neurons.
CC       Interacts with EPHA4; may mediate the activation of NGEF by EPHA4.
CC       Interacts with PTK2/FAK1 (By similarity). The complex p35/CDK5
CC       interacts with CLOCK. Interacts with HTR6 (By similarity).
CC       {ECO:0000250, ECO:0000250|UniProtKB:P49615,
CC       ECO:0000269|PubMed:11583627, ECO:0000269|PubMed:14521924,
CC       ECO:0000269|PubMed:15689152, ECO:0000269|PubMed:17009320,
CC       ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17671990,
CC       ECO:0000269|PubMed:19693690, ECO:0000269|PubMed:21668448,
CC       ECO:0000269|PubMed:24235147}.
CC   -!- INTERACTION:
CC       Q00535; P61158: ACTR3; NbExp=3; IntAct=EBI-1041567, EBI-351428;
CC       Q00535; P05067: APP; NbExp=3; IntAct=EBI-1041567, EBI-77613;
CC       Q00535; P23560-2: BDNF; NbExp=3; IntAct=EBI-1041567, EBI-12275524;
CC       Q00535; Q8TDN4: CABLES1; NbExp=7; IntAct=EBI-1041567, EBI-604615;
CC       Q00535; P24863: CCNC; NbExp=2; IntAct=EBI-1041567, EBI-395261;
CC       Q00535; P30279: CCND2; NbExp=16; IntAct=EBI-1041567, EBI-748789;
CC       Q00535; P30281: CCND3; NbExp=10; IntAct=EBI-1041567, EBI-375013;
CC       Q00535; Q14094: CCNI; NbExp=4; IntAct=EBI-1041567, EBI-1104653;
CC       Q00535; Q15078: CDK5R1; NbExp=13; IntAct=EBI-1041567, EBI-746189;
CC       Q00535; P38936: CDKN1A; NbExp=5; IntAct=EBI-1041567, EBI-375077;
CC       Q00535; P46527: CDKN1B; NbExp=11; IntAct=EBI-1041567, EBI-519280;
CC       Q00535; Q9UJC3: HOOK1; NbExp=3; IntAct=EBI-1041567, EBI-746704;
CC       Q00535; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-1041567, EBI-16439278;
CC       Q00535; Q9Y6R0: NUMBL; NbExp=3; IntAct=EBI-1041567, EBI-945925;
CC       Q00535; P37231-2: PPARG; NbExp=2; IntAct=EBI-1041567, EBI-781416;
CC       Q00535; P62937: PPIA; NbExp=3; IntAct=EBI-1041567, EBI-437708;
CC       Q00535; O60260-5: PRKN; NbExp=3; IntAct=EBI-1041567, EBI-21251460;
CC       Q00535; Q5MJ70: SPDYA; NbExp=3; IntAct=EBI-1041567, EBI-7125479;
CC       Q00535; A6NLX3: SPDYE4; NbExp=4; IntAct=EBI-1041567, EBI-12047907;
CC       Q00535; P20226: TBP; NbExp=3; IntAct=EBI-1041567, EBI-355371;
CC       Q00535; P09936: UCHL1; NbExp=2; IntAct=EBI-1041567, EBI-714860;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cytoplasm
CC       {ECO:0000269|PubMed:12691662}. Nucleus {ECO:0000269|PubMed:12691662}.
CC       Cell membrane {ECO:0000269|PubMed:17009320}; Peripheral membrane
CC       protein. Perikaryon. Cell projection, lamellipodium
CC       {ECO:0000250|UniProtKB:P49615}. Cell projection, growth cone
CC       {ECO:0000250|UniProtKB:P49615}. Postsynaptic density
CC       {ECO:0000250|UniProtKB:Q03114}. Synapse {ECO:0000250|UniProtKB:Q03114}.
CC       Note=In axonal growth cone with extension to the peripheral
CC       lamellipodia (By similarity). Under neurotoxic stress and neuronal
CC       injury conditions, CDK5R (p35) is cleaved by calpain to generate CDK5R1
CC       (p25) in response to increased intracellular calcium. The elevated
CC       level of p25, when in complex with CDK5, leads to its subcellular
CC       misallocation as well as its hyperactivation. Colocalizes with CTNND2
CC       in the cell body of neuronal cells, and with CTNNB1 in the cell-cell
CC       contacts and plasma membrane of undifferentiated and differentiated
CC       neuroblastoma cells. Reversibly attached to the plasma membrane in an
CC       inactive form when complexed to dephosphorylated p35 or CDK5R2 (p39),
CC       p35 phosphorylation releases this attachment and activates CDK5.
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q00535-1; Sequence=Displayed;
CC       Name=2; Synonyms=CDK5-SV {ECO:0000303|PubMed:19693690};
CC         IsoId=Q00535-2; Sequence=VSP_041948;
CC   -!- TISSUE SPECIFICITY: [Isoform 1]: Ubiquitously expressed
CC       (PubMed:17009320, PubMed:19693690). Accumulates in cortical neurons (at
CC       protein level) (PubMed:17009320). {ECO:0000269|PubMed:17009320,
CC       ECO:0000269|PubMed:19693690}.
CC   -!- TISSUE SPECIFICITY: [Isoform 2]: Expressed in the testis, skeletal
CC       muscle, colon, bone marrow and ovary. {ECO:0000269|PubMed:19693690}.
CC   -!- PTM: Phosphorylation on Tyr-15 by ABL1 and FYN, and on Ser-159 by
CC       casein kinase 1 promotes kinase activity. By contrast, phosphorylation
CC       at Thr-14 inhibits activity. {ECO:0000269|PubMed:10500146,
CC       ECO:0000269|PubMed:15689152, ECO:0000269|PubMed:17143272}.
CC   -!- PTM: Phosphorylation at Ser-159 is essential for maximal catalytic
CC       activity. {ECO:0000269|PubMed:10500146}.
CC   -!- DISEASE: Lissencephaly 7, with cerebellar hypoplasia (LIS7)
CC       [MIM:616342]: A form of lissencephaly, a disorder of cortical
CC       development characterized by agyria or pachygyria and disorganization
CC       of the clear neuronal lamination of normal six-layered cortex. LIS7
CC       patients manifest lack of psychomotor development, facial dysmorphism,
CC       arthrogryposis, and early-onset intractable seizures resulting in death
CC       in infancy. {ECO:0000269|PubMed:25560765}. Note=The disease is caused
CC       by variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Dysregulation of CDK5 is associated with
CC       neurodegenerative disorders such as Alzheimer, Parkinson, and Niemann-
CC       Pick type C diseases, ischemia, and amyotrophic lateral sclerosis.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X66364; CAA47007.1; -; mRNA.
DR   EMBL; DQ411039; ABD66016.1; -; mRNA.
DR   EMBL; AY049778; AAL15435.1; -; mRNA.
DR   EMBL; BT006680; AAP35326.1; -; mRNA.
DR   EMBL; AC010973; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC005115; AAH05115.1; -; mRNA.
DR   CCDS; CCDS47748.1; -. [Q00535-1]
DR   CCDS; CCDS55184.1; -. [Q00535-2]
DR   PIR; S23386; S23386.
DR   RefSeq; NP_001157882.1; NM_001164410.2. [Q00535-2]
DR   RefSeq; NP_004926.1; NM_004935.3. [Q00535-1]
DR   PDB; 1H4L; X-ray; 2.65 A; A/B=1-292.
DR   PDB; 1UNG; X-ray; 2.30 A; A/B=1-292.
DR   PDB; 1UNH; X-ray; 2.35 A; A/B=1-292.
DR   PDB; 1UNL; X-ray; 2.20 A; A/B=1-292.
DR   PDB; 3O0G; X-ray; 1.95 A; A/B=1-292.
DR   PDB; 4AU8; X-ray; 1.90 A; A/B=2-292.
DR   PDB; 7VDP; X-ray; 2.09 A; A/B=2-292.
DR   PDB; 7VDQ; X-ray; 2.91 A; A/B=2-292.
DR   PDB; 7VDR; X-ray; 2.55 A; A/B=2-292.
DR   PDB; 7VDS; X-ray; 3.05 A; A/B=2-292.
DR   PDBsum; 1H4L; -.
DR   PDBsum; 1UNG; -.
DR   PDBsum; 1UNH; -.
DR   PDBsum; 1UNL; -.
DR   PDBsum; 3O0G; -.
DR   PDBsum; 4AU8; -.
DR   PDBsum; 7VDP; -.
DR   PDBsum; 7VDQ; -.
DR   PDBsum; 7VDR; -.
DR   PDBsum; 7VDS; -.
DR   AlphaFoldDB; Q00535; -.
DR   SMR; Q00535; -.
DR   BioGRID; 107455; 178.
DR   ComplexPortal; CPX-2201; Cyclin-dependent protein kinase 5 holoenzyme complex, p35 variant.
DR   ComplexPortal; CPX-3141; Cyclin-dependent protein kinase 5 holoenzyme complex, p39 variant.
DR   ComplexPortal; CPX-3142; Cyclin-dependent protein kinase 5 holoenzyme complex, p25 variant.
DR   CORUM; Q00535; -.
DR   DIP; DIP-24221N; -.
DR   ELM; Q00535; -.
DR   IntAct; Q00535; 80.
DR   MINT; Q00535; -.
DR   STRING; 9606.ENSP00000419782; -.
DR   BindingDB; Q00535; -.
DR   ChEMBL; CHEMBL4036; -.
DR   DrugBank; DB07364; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE.
DR   DrugBank; DB04014; Alsterpaullone.
DR   DrugBank; DB03496; Alvocidib.
DR   DrugBank; DB02950; Hymenialdisine.
DR   DrugBank; DB02052; Indirubin-3'-monoxime.
DR   DrugBank; DB02116; Olomoucine.
DR   DrugBank; DB03428; SU9516.
DR   DrugBank; DB15442; Trilaciclib.
DR   DrugCentral; Q00535; -.
DR   GuidetoPHARMACOLOGY; 1977; -.
DR   GlyGen; Q00535; 4 sites, 1 O-linked glycan (4 sites).
DR   iPTMnet; Q00535; -.
DR   PhosphoSitePlus; Q00535; -.
DR   SwissPalm; Q00535; -.
DR   BioMuta; CDK5; -.
DR   DMDM; 4033704; -.
DR   EPD; Q00535; -.
DR   jPOST; Q00535; -.
DR   MassIVE; Q00535; -.
DR   MaxQB; Q00535; -.
DR   PaxDb; Q00535; -.
DR   PeptideAtlas; Q00535; -.
DR   PRIDE; Q00535; -.
DR   ProteomicsDB; 57852; -. [Q00535-1]
DR   ProteomicsDB; 57853; -. [Q00535-2]
DR   Antibodypedia; 4556; 1035 antibodies from 41 providers.
DR   DNASU; 1020; -.
DR   Ensembl; ENST00000297518.4; ENSP00000297518.4; ENSG00000164885.13. [Q00535-2]
DR   Ensembl; ENST00000485972.6; ENSP00000419782.1; ENSG00000164885.13. [Q00535-1]
DR   GeneID; 1020; -.
DR   KEGG; hsa:1020; -.
DR   MANE-Select; ENST00000485972.6; ENSP00000419782.1; NM_004935.4; NP_004926.1.
DR   UCSC; uc003wir.3; human. [Q00535-1]
DR   CTD; 1020; -.
DR   DisGeNET; 1020; -.
DR   GeneCards; CDK5; -.
DR   HGNC; HGNC:1774; CDK5.
DR   HPA; ENSG00000164885; Tissue enhanced (brain).
DR   MalaCards; CDK5; -.
DR   MIM; 123831; gene.
DR   MIM; 616342; phenotype.
DR   neXtProt; NX_Q00535; -.
DR   OpenTargets; ENSG00000164885; -.
DR   PharmGKB; PA26310; -.
DR   VEuPathDB; HostDB:ENSG00000164885; -.
DR   eggNOG; KOG0662; Eukaryota.
DR   GeneTree; ENSGT00940000160805; -.
DR   HOGENOM; CLU_000288_181_1_1; -.
DR   InParanoid; Q00535; -.
DR   OMA; QHPWFND; -.
DR   PhylomeDB; Q00535; -.
DR   TreeFam; TF101023; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   BRENDA; 2.7.11.22; 2681.
DR   PathwayCommons; Q00535; -.
DR   Reactome; R-HSA-180024; DARPP-32 events.
DR   Reactome; R-HSA-399956; CRMPs in Sema3A signaling.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-8862803; Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models.
DR   Reactome; R-HSA-9031628; NGF-stimulated transcription.
DR   Reactome; R-HSA-9032845; Activated NTRK2 signals through CDK5.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; Q00535; -.
DR   SIGNOR; Q00535; -.
DR   BioGRID-ORCS; 1020; 25 hits in 1121 CRISPR screens.
DR   ChiTaRS; CDK5; human.
DR   EvolutionaryTrace; Q00535; -.
DR   GeneWiki; Cyclin-dependent_kinase_5; -.
DR   GenomeRNAi; 1020; -.
DR   Pharos; Q00535; Tchem.
DR   PRO; PR:Q00535; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q00535; protein.
DR   Bgee; ENSG00000164885; Expressed in right frontal lobe and 154 other tissues.
DR   ExpressionAtlas; Q00535; baseline and differential.
DR   Genevisible; Q00535; HS.
DR   GO; GO:0070161; C:anchoring junction; IEA:UniProtKB-KW.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0000307; C:cyclin-dependent protein kinase holoenzyme complex; IPI:ComplexPortal.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0030175; C:filopodium; IEA:Ensembl.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0030426; C:growth cone; ISS:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; ISS:UniProtKB.
DR   GO; GO:0005874; C:microtubule; IEA:Ensembl.
DR   GO; GO:0031594; C:neuromuscular junction; ISS:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; ISS:ARUK-UCL.
DR   GO; GO:0043025; C:neuronal cell body; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0043204; C:perikaryon; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0014069; C:postsynaptic density; ISS:UniProtKB.
DR   GO; GO:0098793; C:presynapse; IEA:Ensembl.
DR   GO; GO:0016533; C:protein kinase 5 complex; IPI:ComplexPortal.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl.
DR   GO; GO:0030549; F:acetylcholine receptor activator activity; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0046875; F:ephrin receptor binding; IEA:Ensembl.
DR   GO; GO:0005176; F:ErbB-2 class receptor binding; ISS:UniProtKB.
DR   GO; GO:0043125; F:ErbB-3 class receptor binding; ISS:UniProtKB.
DR   GO; GO:0051879; F:Hsp90 protein binding; IEA:Ensembl.
DR   GO; GO:0016301; F:kinase activity; ISS:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IEA:Ensembl.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL.
DR   GO; GO:0050321; F:tau-protein kinase activity; ISS:UniProtKB.
DR   GO; GO:0099635; F:voltage-gated calcium channel activity involved in positive regulation of presynaptic cytosolic calcium levels; IEA:Ensembl.
DR   GO; GO:0048675; P:axon extension; TAS:UniProtKB.
DR   GO; GO:0007409; P:axonogenesis; IBA:GO_Central.
DR   GO; GO:0048148; P:behavioral response to cocaine; IEA:Ensembl.
DR   GO; GO:0070509; P:calcium ion import; IEA:Ensembl.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0007160; P:cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:1904646; P:cellular response to amyloid-beta; ISS:ARUK-UCL.
DR   GO; GO:0021954; P:central nervous system neuron development; IEA:Ensembl.
DR   GO; GO:0021697; P:cerebellar cortex formation; IEA:Ensembl.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:UniProtKB.
DR   GO; GO:0022038; P:corpus callosum development; IEA:Ensembl.
DR   GO; GO:0030866; P:cortical actin cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0048813; P:dendrite morphogenesis; IEA:Ensembl.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; IEA:Ensembl.
DR   GO; GO:0021766; P:hippocampus development; IEA:Ensembl.
DR   GO; GO:0006886; P:intracellular protein transport; IEA:Ensembl.
DR   GO; GO:0021819; P:layer formation in cerebral cortex; IEA:Ensembl.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; TAS:ARUK-UCL.
DR   GO; GO:0007005; P:mitochondrion organization; IEA:Ensembl.
DR   GO; GO:0008045; P:motor neuron axon guidance; IEA:Ensembl.
DR   GO; GO:0030517; P:negative regulation of axon extension; IEA:Ensembl.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:DFLAT.
DR   GO; GO:1901215; P:negative regulation of neuron death; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0046826; P:negative regulation of protein export from nucleus; IEA:Ensembl.
DR   GO; GO:0031397; P:negative regulation of protein ubiquitination; IEA:Ensembl.
DR   GO; GO:0045861; P:negative regulation of proteolysis; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0031914; P:negative regulation of synaptic plasticity; IEA:Ensembl.
DR   GO; GO:0051402; P:neuron apoptotic process; IBA:GO_Central.
DR   GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; TAS:UniProtKB.
DR   GO; GO:0031175; P:neuron projection development; ISS:UniProtKB.
DR   GO; GO:0006913; P:nucleocytoplasmic transport; IEA:Ensembl.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; ISS:ARUK-UCL.
DR   GO; GO:0016310; P:phosphorylation; IDA:DFLAT.
DR   GO; GO:2000251; P:positive regulation of actin cytoskeleton reorganization; TAS:UniProtKB.
DR   GO; GO:0045956; P:positive regulation of calcium ion-dependent exocytosis; IEA:Ensembl.
DR   GO; GO:0034352; P:positive regulation of glial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0032092; P:positive regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IEA:Ensembl.
DR   GO; GO:0090314; P:positive regulation of protein targeting to membrane; IEA:Ensembl.
DR   GO; GO:1901387; P:positive regulation of voltage-gated calcium channel activity; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0035418; P:protein localization to synapse; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0032801; P:receptor catabolic process; IEA:Ensembl.
DR   GO; GO:0043113; P:receptor clustering; IEA:Ensembl.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; TAS:UniProtKB.
DR   GO; GO:0030334; P:regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0061001; P:regulation of dendritic spine morphogenesis; ISS:UniProtKB.
DR   GO; GO:0016241; P:regulation of macroautophagy; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1903076; P:regulation of protein localization to plasma membrane; ISS:ARUK-UCL.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; ISS:UniProtKB.
DR   GO; GO:0051966; P:regulation of synaptic transmission, glutamatergic; ISS:ARUK-UCL.
DR   GO; GO:1903421; P:regulation of synaptic vesicle recycling; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0000083; P:regulation of transcription involved in G1/S transition of mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0009611; P:response to wounding; IEA:Ensembl.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0014044; P:Schwann cell development; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0042501; P:serine phosphorylation of STAT protein; IEA:Ensembl.
DR   GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl.
DR   GO; GO:0007416; P:synapse assembly; TAS:UniProtKB.
DR   GO; GO:0098883; P:synapse pruning; IEA:Ensembl.
DR   GO; GO:0001963; P:synaptic transmission, dopaminergic; IEA:Ensembl.
DR   GO; GO:0035249; P:synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0048488; P:synaptic vesicle endocytosis; TAS:UniProtKB.
DR   GO; GO:0016079; P:synaptic vesicle exocytosis; TAS:UniProtKB.
DR   GO; GO:0048489; P:synaptic vesicle transport; IBA:GO_Central.
DR   GO; GO:0008542; P:visual learning; IEA:Ensembl.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding;
KW   Biological rhythms; Cell cycle; Cell division; Cell membrane;
KW   Cell projection; Cytoplasm; Kinase; Lissencephaly; Membrane;
KW   Neurodegeneration; Neurogenesis; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Synapse; Transferase.
FT   CHAIN           1..292
FT                   /note="Cyclin-dependent kinase 5"
FT                   /id="PRO_0000085784"
FT   DOMAIN          4..286
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ACT_SITE        126
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         10..18
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         33
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         15
FT                   /note="Phosphotyrosine; by ABL1, EPHA4 and FYN"
FT                   /evidence="ECO:0000269|PubMed:15689152,
FT                   ECO:0000269|PubMed:17143272"
FT   MOD_RES         17
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         56
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         72
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         159
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:10500146"
FT   VAR_SEQ         105..136
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:19693690"
FT                   /id="VSP_041948"
FT   VARIANT         225
FT                   /note="E -> D (in dbSNP:rs35186917)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041977"
FT   MUTAGEN         159
FT                   /note="S->A: No phenotype."
FT                   /evidence="ECO:0000269|PubMed:11583627"
FT   MUTAGEN         159
FT                   /note="S->T: Impaired p35/p25 (CDK5R1) binding."
FT                   /evidence="ECO:0000269|PubMed:11583627"
FT   STRAND          4..12
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   STRAND          14..23
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   TURN            24..26
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   STRAND          29..36
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   STRAND          40..42
FT                   /evidence="ECO:0007829|PDB:1UNG"
FT   HELIX           46..55
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   STRAND          66..70
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   STRAND          76..81
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   STRAND          84..86
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   HELIX           87..94
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   HELIX           100..119
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   HELIX           129..131
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   STRAND          132..134
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   STRAND          140..142
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   HELIX           145..147
FT                   /evidence="ECO:0007829|PDB:1UNG"
FT   HELIX           165..167
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   HELIX           170..173
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   HELIX           182..196
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   TURN            197..199
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   HELIX           208..219
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   TURN            224..226
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   HELIX           228..232
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   HELIX           248..250
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   HELIX           257..266
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   HELIX           271..273
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   HELIX           277..281
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   HELIX           284..286
FT                   /evidence="ECO:0007829|PDB:4AU8"
FT   STRAND          287..289
FT                   /evidence="ECO:0007829|PDB:7VDQ"
SQ   SEQUENCE   292 AA;  33304 MW;  54D10495F017D527 CRC64;
     MQKYEKLEKI GEGTYGTVFK AKNRETHEIV ALKRVRLDDD DEGVPSSALR EICLLKELKH
     KNIVRLHDVL HSDKKLTLVF EFCDQDLKKY FDSCNGDLDP EIVKSFLFQL LKGLGFCHSR
     NVLHRDLKPQ NLLINRNGEL KLADFGLARA FGIPVRCYSA EVVTLWYRPP DVLFGAKLYS
     TSIDMWSAGC IFAELANAGR PLFPGNDVDD QLKRIFRLLG TPTEEQWPSM TKLPDYKPYP
     MYPATTSLVN VVPKLNATGR DLLQNLLKCN PVQRISAEEA LQHPYFSDFC PP
//
